retatrutide obesity triple hormone receptor agonist ⭐️topline results from TRIUMPH-1, a Phase 3 clinical trial evaluating #retatrutide, an investigational GIP / GLP-1 / glucagon agonist, in adults with or “overweight” Triple Agonism Based Therapies for

The Phase 3 TRIUMPH-4 trial confirmed and exceeded those expectations

Tirzepatide: a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) dual agonist in development for the treatment of type 2 diabetes

Kidney Week, November 1520 (2016)

Data Availability Sharing is not applicable to this article as no datasets were generated or analyzed during the current study

Comparative Safety of GLP-1/GIP Co-Agonists Versus GLP-1 Receptor Agonists for Weight Loss: A Systematic Review

Side effects, particularly nausea, fatigue, constipation and reflux, are most pronounced in the first four to eight weeks of treatment as the dose increases